Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.

Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C.

BMC Cancer. 2019 Aug 29;19(1):855. doi: 10.1186/s12885-019-6080-8.

2.

Disruption of IRE1α through its kinase domain attenuates multiple myeloma.

Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A.

Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. doi: 10.1073/pnas.1906999116. Epub 2019 Aug 1.

3.

Improvement of diet sustainability with increased level of organic food in the diet: findings from the BioNutriNet cohort.

Baudry J, Pointereau P, Seconda L, Vidal R, Taupier-Letage B, Langevin B, Allès B, Galan P, Hercberg S, Amiot MJ, Boizot-Szantai C, Hamza O, Cravedi JP, Debrauwer L, Soler LG, Lairon D, Kesse-Guyot E.

Am J Clin Nutr. 2019 Apr 1;109(4):1173-1188. doi: 10.1093/ajcn/nqy361.

PMID:
30982857
4.

CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.

Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, Moreau P, Touzeau C, Amiot M, Pellat-Deceunynck C, Le Gouill S, Chiron D.

Leukemia. 2019 Oct;33(10):2442-2453. doi: 10.1038/s41375-019-0463-3. Epub 2019 Apr 2.

PMID:
30940906
5.

Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells.

Tessoulin B, Descamps G, Dousset C, Amiot M, Pellat-Deceunynck C.

Front Oncol. 2019 Mar 6;9:128. doi: 10.3389/fonc.2019.00128. eCollection 2019.

6.

Some Differences in Nutritional Biomarkers are Detected Between Consumers and Nonconsumers of Organic Foods: Findings from the BioNutriNet Project.

Baudry J, Ducros V, Druesne-Pecollo N, Galan P, Hercberg S, Debrauwer L, Amiot MJ, Lairon D, Kesse-Guyot E.

Curr Dev Nutr. 2018 Nov 15;3(3):nzy090. doi: 10.1093/cdn/nzy090. eCollection 2019 Mar.

7.

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.

Tessoulin B, Papin A, Gomez-Bougie P, Bellanger C, Amiot M, Pellat-Deceunynck C, Chiron D.

Front Oncol. 2019 Jan 7;8:645. doi: 10.3389/fonc.2018.00645. eCollection 2018.

8.

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers.

Louault K, Bonneaud TL, Séveno C, Gomez-Bougie P, Nguyen F, Gautier F, Bourgeois N, Loussouarn D, Kerdraon O, Barillé-Nion S, Jézéquel P, Campone M, Amiot M, Juin PP, Souazé F.

Oncogene. 2019 Apr;38(17):3261-3273. doi: 10.1038/s41388-018-0635-z. Epub 2019 Jan 10.

9.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C.

J Hematol Oncol. 2018 Dec 13;11(1):137. doi: 10.1186/s13045-018-0679-0.

10.

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C.

Blood Adv. 2018 Dec 11;2(23):3492-3505. doi: 10.1182/bloodadvances.2018025106.

11.

Nutritional Composition and Bioactive Content of Legumes: Characterization of Pulses Frequently Consumed in France and Effect of the Cooking Method.

Margier M, Georgé S, Hafnaoui N, Remond D, Nowicki M, Du Chaffaut L, Amiot MJ, Reboul E.

Nutrients. 2018 Nov 4;10(11). pii: E1668. doi: 10.3390/nu10111668.

12.

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.

Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, Le Gouill S, Touzeau C, Moreau P, Pellat-Deceunynck C, Amiot M.

Blood. 2018 Dec 20;132(25):2656-2669. doi: 10.1182/blood-2018-03-836718. Epub 2018 Oct 11.

13.

Targeting Bcl-2 for the treatment of multiple myeloma.

Touzeau C, Maciag P, Amiot M, Moreau P.

Leukemia. 2018 Sep;32(9):1899-1907. doi: 10.1038/s41375-018-0223-9. Epub 2018 Aug 3. Review.

PMID:
30076373
14.

A "Fork-to-Farm" Multi-Scale Approach to Promote Sustainable Food Systems for Nutrition and Health: A Perspective for the Mediterranean Region.

Verger EO, Perignon M, El Ati J, Darmon N, Dop MC, Drogué S, Dury S, Gaillard C, Sinfort C, Amiot MJ; MEDINA-Study Group.

Front Nutr. 2018 May 22;5:30. doi: 10.3389/fnut.2018.00030. eCollection 2018.

15.

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard AM, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin JM, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJS, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O.

Oncotarget. 2018 Apr 13;9(28):20075-20088. doi: 10.18632/oncotarget.24744. eCollection 2018 Apr 13.

16.

Effects of Exercise Intensity on Microvascular Function in Obese Adolescents.

Morrissey C, Montero D, Raverdy C, Masson D, Amiot MJ, Vinet A.

Int J Sports Med. 2018 Jun;39(6):450-455. doi: 10.1055/a-0577-4280. Epub 2018 Apr 30.

PMID:
29710370
17.

Integrating nutrient bioavailability and co-production links when identifying sustainable diets: How low should we reduce meat consumption?

Barré T, Perignon M, Gazan R, Vieux F, Micard V, Amiot MJ, Darmon N.

PLoS One. 2018 Feb 14;13(2):e0191767. doi: 10.1371/journal.pone.0191767. eCollection 2018.

18.

Effects of cooking and food matrix on estimated mineral bioavailability in Mloukhiya, a Mediterranean dish based on jute leaves and meat.

Njoumi S, Bellagha S, Icard-Vernière C, Picq C, Amiot MJ, Mouquet-Rivier C.

Food Res Int. 2018 Mar;105:233-240. doi: 10.1016/j.foodres.2017.11.020. Epub 2017 Nov 21.

PMID:
29433211
19.

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.

Gillardin PS, Descamps G, Maiga S, Tessoulin B, Djamai H, Lucani B, Chiron D, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C, Moreau-Aubry A.

Int J Mol Sci. 2017 Dec 23;19(1). pii: E40. doi: 10.3390/ijms19010040.

20.

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A.

Cancer Discov. 2017 Dec;7(12):1376-1393. doi: 10.1158/2159-8290.CD-17-0797. Epub 2017 Nov 16. Review.

21.

Involvement of bilitranslocase and beta-glucuronidase in the vascular protection by hydroxytyrosol and its glucuronide metabolites in oxidative stress conditions.

Peyrol J, Meyer G, Obert P, Dangles O, Pechère L, Amiot MJ, Riva C.

J Nutr Biochem. 2018 Jan;51:8-15. doi: 10.1016/j.jnutbio.2017.09.009. Epub 2017 Oct 3.

PMID:
29078076
22.

Large irradiation doses can improve the fast neutron/gamma discriminating capability of plastic scintillators.

Montbarbon E, Amiot MN, Tromson D, Gaillard S, Frangville C, Woo R, Bertrand GHV, Pansu RB, Renaud JL, Hamel M.

Phys Chem Chem Phys. 2017 Oct 25;19(41):28105-28115. doi: 10.1039/c7cp04034b.

PMID:
29019483
23.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

PMID:
29018077
24.

The bioavailability of iron, zinc, protein and vitamin A is highly variable in French individual diets: Impact on nutrient inadequacy assessment and relation with the animal-to-plant ratio of diets.

Perignon M, Barré T, Gazan R, Amiot MJ, Darmon N.

Food Chem. 2018 Jan 1;238:73-81. doi: 10.1016/j.foodchem.2016.12.070. Epub 2016 Dec 22.

PMID:
28867104
25.

Fat-soluble micronutrients and metabolic syndrome.

Goncalves A, Amiot MJ.

Curr Opin Clin Nutr Metab Care. 2017 Nov;20(6):492-497. doi: 10.1097/MCO.0000000000000412. Review.

26.

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.

Guikema JE, Amiot M, Eldering E.

Expert Opin Ther Targets. 2017 Aug;21(8):767-779. doi: 10.1080/14728222.2017.1349754. Epub 2017 Jul 18. Review.

PMID:
28670929
27.

Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders.

Peyrol J, Riva C, Amiot MJ.

Nutrients. 2017 Mar 20;9(3). pii: E306. doi: 10.3390/nu9030306. Review.

28.

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.

Tessoulin B, Eveillard M, Lok A, Chiron D, Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S, Pellat-Deceunynck C.

Blood Rev. 2017 Jul;31(4):251-259. doi: 10.1016/j.blre.2017.03.001. Epub 2017 Mar 4. Review.

PMID:
28284458
29.

Food Choice Motives When Purchasing in Organic and Conventional Consumer Clusters: Focus on Sustainable Concerns (The NutriNet-Santé Cohort Study).

Baudry J, Péneau S, Allès B, Touvier M, Hercberg S, Galan P, Amiot MJ, Lairon D, Méjean C, Kesse-Guyot E.

Nutrients. 2017 Jan 24;9(2). pii: E88. doi: 10.3390/nu9020088.

30.

Evidence against solar influence on nuclear decay constants.

Pommé S, Stroh H, Paepen J, Van Ammel R, Marouli M, Altzitzoglou T, Hult M, Kossert K, Nähle O, Schrader H, Juget F, Bailat C, Nedjadi Y, Bochud F, Buchillier T, Michotte C, Courte S, van Rooy MW, van Staden MJ, Lubbe J, Simpson BR, Fazio A, De Felice P, Jackson TW, Van Wyngaardt WM, Reinhard MI, Golya J, Bourke S, Roy T, Galea R, Keightley JD, Ferreira KM, Collins SM, Ceccatelli A, Unterweger M, Fitzgerald R, Bergeron DE, Pibida L, Verheyen L, Bruggeman M, Vodenik B, Korun M, Chisté V, Amiot MN.

Phys Lett B. 2016 Oct;761:281-286. doi: 10.1016/j.physletb.2016.08.038. Epub 2016 Aug 24.

31.

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Touzeau C, Le Gouill S, Mahé B, Boudreault JS, Gastinne T, Blin N, Caillon H, Dousset C, Amiot M, Moreau P.

Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5. No abstract available.

32.

Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.

Gomez-Bougie P, Halliez M, Moreau P, Pellat-Deceunynck C, Amiot M.

Cancer Lett. 2016 Dec 28;383(2):204-211. doi: 10.1016/j.canlet.2016.09.030. Epub 2016 Sep 30.

PMID:
27697610
33.

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.

Hanf M, Chiron D, de Visme S, Touzeau C, Maisonneuve H, Jardel H, Pellat-Deceunynck C, Amiot M, le Gouill S.

BMC Cancer. 2016 Oct 14;16(1):802.

34.

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.

Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, Moreau A, Esbelin J, Trichet V, Chen-Kiang S, Moreau P, Touzeau C, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Blood. 2016 Dec 15;128(24):2808-2818. Epub 2016 Oct 3.

PMID:
27697772
35.

Reaching Nutritional Adequacy Does Not Necessarily Increase Exposure to Food Contaminants: Evidence from a Whole-Diet Modeling Approach.

Barré T, Vieux F, Perignon M, Cravedi JP, Amiot MJ, Micard V, Darmon N.

J Nutr. 2016 Oct;146(10):2149-2157. Epub 2016 Sep 14.

PMID:
27629574
36.

A Consensus Proposal for Nutritional Indicators to Assess the Sustainability of a Healthy Diet: The Mediterranean Diet as a Case Study.

Donini LM, Dernini S, Lairon D, Serra-Majem L, Amiot MJ, Del Balzo V, Giusti AM, Burlingame B, Belahsen R, Maiani G, Polito A, Turrini A, Intorre F, Trichopoulou A, Berry EM.

Front Nutr. 2016 Aug 29;3:37. doi: 10.3389/fnut.2016.00037. eCollection 2016.

37.

The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.

Gomez-Bougie P, Dousset C, Descamps G, Schnitzler A, Audiger L, Tessier A, Dubreuil D, Lebreton J, Pellat-Deceunynck C, Amiot M.

Br J Haematol. 2018 Jan;180(1):157-159. doi: 10.1111/bjh.14293. Epub 2016 Aug 14. No abstract available.

PMID:
27523575
38.

BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.

Dousset C, Maïga S, Gomez-Bougie P, Le Coq J, Touzeau C, Moreau P, Le Gouill S, Chiron D, Pellat-Deceunynck C, Moreau-Aubry A, Amiot M.

Br J Haematol. 2017 Nov;179(4):684-688. doi: 10.1111/bjh.14251. Epub 2016 Jul 29. No abstract available.

PMID:
27471002
39.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

40.

Culinary practices mimicking a polysaccharide-rich recipe enhance the bioaccessibility of fat-soluble micronutrients.

Dhuique-Mayer C, Servent A, Descalzo A, Mouquet-Rivier C, Amiot MJ, Achir N.

Food Chem. 2016 Nov 1;210:182-8. doi: 10.1016/j.foodchem.2016.04.037. Epub 2016 Apr 28.

PMID:
27211637
41.

Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review.

Amiot MJ, Riva C, Vinet A.

Obes Rev. 2016 Jul;17(7):573-86. doi: 10.1111/obr.12409. Epub 2016 Apr 15. Review.

PMID:
27079631
42.

How low can dietary greenhouse gas emissions be reduced without impairing nutritional adequacy, affordability and acceptability of the diet? A modelling study to guide sustainable food choices.

Perignon M, Masset G, Ferrari G, Barré T, Vieux F, Maillot M, Amiot MJ, Darmon N.

Public Health Nutr. 2016 Oct;19(14):2662-74. doi: 10.1017/S1368980016000653. Epub 2016 Apr 6.

PMID:
27049598
43.

Pinoresinol of olive oil decreases vitamin D intestinal absorption.

Goncalves A, Margier M, Tagliaferri C, Lebecque P, Georgé S, Wittrant Y, Coxam V, Amiot MJ, Reboul E.

Food Chem. 2016 Sep 1;206:234-8. doi: 10.1016/j.foodchem.2016.03.048. Epub 2016 Mar 16.

PMID:
27041321
44.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.

Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.

45.

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, Giuliani N.

Haematologica. 2016 Mar;101(3):e107-10. doi: 10.3324/haematol.2015.133736. Epub 2015 Dec 11. No abstract available.

46.

Investigation of the response variability of ionization chambers for the standard transfer of SIR-Spheres(®).

Thiam C, Bobin C, Lourenço V, Chisté V, Amiot MN, Mougeot X, Lacour D, Rigoulay F, Ferreux L.

Appl Radiat Isot. 2016 Mar;109:231-235. doi: 10.1016/j.apradiso.2015.11.056. Epub 2015 Nov 22.

PMID:
26651176
47.

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.

Kervoëlen C, Ménoret E, Gomez-Bougie P, Bataille R, Godon C, Marionneau-Lambot S, Moreau P, Pellat-Deceunynck C, Amiot M.

Oncotarget. 2015 Sep 29;6(29):26922-34. doi: 10.18632/oncotarget.4616.

48.

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.

Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A.

Leukemia. 2016 Mar;30(3):761-4. doi: 10.1038/leu.2015.184. Epub 2015 Jul 15. No abstract available.

49.

Micellar lipid composition affects micelle interaction with class B scavenger receptor extracellular loops.

Goncalves A, Gontero B, Nowicki M, Margier M, Masset G, Amiot MJ, Reboul E.

J Lipid Res. 2015 Jun;56(6):1123-33. doi: 10.1194/jlr.M057612. Epub 2015 Apr 1.

50.

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, Pellat-Deceunynck C, Le Gouill S, Amiot M.

Oncotarget. 2015 Apr 20;6(11):8750-9.

Supplemental Content

Support Center